Skip to main content
Smart Investors Daily
DE

NASDAQ · DECA

Denali Capital Acquisition Corp.

Financial Services · Shell Companies

$11.43

Down-$0.38 (-3.22%)

Updated Aug 16, 2026, 8:38 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
38.56M
P/E ratio
-1.29
Dividend yield
0.00%
52-week range
— – —
Volume
3.63K
Avg. volume
323

Price performance

DECA price history

1M range · 0 trading sessions · Daily adjusted prices

DECA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest DECA news

The latest Smart Investors Daily articles mentioning DECA.

DECA research

Overview

Company profile and research snapshot.

Company profile

Denali Capital Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. It intends to complete a business combination with companies primarily operating in the technology, consumer, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Oct 28, 2024

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Scilex Holding Company announced a dividend of preferred stock exchangeable for up to 10% of its ownership in Semnur Pharmaceuticals, a wholly-owned subsidiary. The record date is set for November 7, 2024, and the preferred stock is expected to be freely tradable upon exchange.

GlobeNewswire Inc. · Oct 16, 2024

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Semnur Pharmaceuticals, a subsidiary of Scilex Holding, plans to file a registration statement with the SEC in October 2024 for a proposed $2.5 billion business combination with Denali Capital Acquisition Corp. The transaction is expected to close by the end of 2024 or early 2025.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.